Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Syed Mustafa

Allergy & Immunology Rochester, NY Medical Doctor

NPI 1619023223 CMS profile 27964

2300 W Ridge Rd, 5Th Floor, Rochester, NY 14626

Open in the dashboard

General payments

$948,400

845 records reported · program years 2019–2025

Research payments

$15,837

Paid to them · 15 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,700,564 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Syed Mustafa of Rochester, NY is reported in the CMS Open Payments database as having received $948,400 across 845 general payments and $15,837 in research payments paid to them. Separately, studies naming them as principal investigator received $2,700,564 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $190,494 179
2024 General $144,119 123
2024 Research $9,055 6
2023 General $159,604 126
2023 Research $6,781 9
2022 General $133,507 113
2021 General $157,864 122
2020 General $65,310 84
2019 General $97,502 98

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Syed Mustafa
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Syed Mustafa were reported at $190,494. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Syed Mustafa Allergy & Immunology median Middle half National median
2019 $97,502 $594 $163–$1,512 $163
2020 $65,310 $426 $106–$1,233 $114
2021 $157,864 $638 $157–$1,708 $132
2022 $133,507 $790 $205–$1,961 $149
2023 $159,604 $852 $220–$2,147 $160
2024 $144,119 $865 $203–$2,267 $164
2025 $190,494 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $203,537 234 payments
  2. Genzyme Corporation $186,347 129 payments
  3. Regeneron Healthcare Solutions, Inc. $121,820 101 payments
  4. GlaxoSmithKline, LLC. $120,655 91 payments
  5. Genentech USA, Inc. $107,217 108 payments
  6. CSL Behring $92,151 60 payments
  7. Aimmune Therapeutics, Inc. $28,982 17 payments
  8. Regeneron Pharmaceuticals, Inc. $22,414 18 payments
  9. Amgen Inc. $12,351 13 payments
  10. ARS Pharmaceuticals Operations, Inc. $12,185 9 payments
  11. Other $40,742 65 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $687,452 281 payments
  2. Consulting Fee $161,593 82 payments
  3. Travel and Lodging $43,108 124 payments
  4. Honoraria $29,811 18 payments
  5. Food and Beverage $26,327 338 payments
  6. Education $109 2 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $193,899 137 payments
  2. DUPIXENT Inflammation And Immunology $124,167 101 payments
  3. Hizentra $92,118 59 payments
  4. NUCALA $90,201 64 payments
  5. Xolair $87,283 94 payments
  6. TEZSPIRE $66,673 65 payments
  7. Privigen $53,647 18 payments
  8. AIRSUPRA $40,487 35 payments
  9. PALFORZIA $23,707 14 payments
  10. FASENRA $22,785 33 payments
  11. Other $112,682 158 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $14,190 13 payments
  2. Regeneron Pharmaceuticals, Inc. $1,647 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

473

Median for Allergy/ Immunology: 449

Drug cost

$528,541

Median for Allergy/ Immunology: $169,700

Branded share of claims

54.3%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tezspire Tezepelumab-Ekko Brand 30 $146,173
Dupixent Pen Dupilumab Brand 27 $108,891
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 13 $92,227
Xolair Omalizumab Brand 32 $80,868
Hyqvia Igg/Hyaluronidase,recombinant Brand 12 $48,840
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 36 $25,386
Breo Ellipta Fluticasone/Vilanterol Brand 17 $8,515
Dulera Mometasone/Formoterol Brand 14 $4,730
Symbicort Budesonide/Formoterol Fumarate Brand 16 $3,449
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 22 $3,071

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$6,639

Medicare's payments for the services billed

Medicare patients

67

Average age 70

Services billed

230

41 women, 26 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 51%
Diabetes 28%
Depression 28%
Chronic kidney disease 22%
Ischemic heart disease 19%
Heart failure 18%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$45,563 27 —
XOLAIR
$23,406 32 —
NUCALA
$20,322 — —
TEZSPIRE
$15,631 30 —
AIRSUPRA
$14,327 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

860 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record